Work

The RB–IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity

Year: 2017

Type: article

Source: Oncogene

DOI: 10.1038/onc.2017.124

Authors: S Kitajima, A Yoshida, S Kohno, F Li, S Suzuki, N Nagatani, Y Nishimoto, N Sasaki, H Muranaka, Y Wan, T C Thai, N Okahashi, F Matsuda, H Shimizu, T Nishiuchi, Y Suzuki, K Tominaga, N Gotoh, M Suzuki, M E Ewen, D A Barbie, O Hirose, T Tanaka, C Takahashi

Institutions: Kanazawa University, Dana-Farber Cancer Institute, Chiba University, The University of Osaka, Advanced Science Research Center, The University of Tokyo, Tufts Medical Center, Broad Institute

Language: English

Topic: Cytokine Signaling Pathways and Interactions

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: World Bank Group, Chugai Pharmaceutical, Japan Society for the Promotion of Science

Awards: Metabolic regulation by RB tumor suppressor gene, Tumor progression through epigenetics remodeling by RB-PGAM, 乳がんにおけるがん抑制遺伝子ＲＢの機能とその作用機構の探索, Drug discovery based on collateral lethality

OpenAlex ID: W2612207404

FWCI: 1.939

Cites: 70

Cited by: 52

Related to: 10